VANDA PHARMACEUTICALS INC. Accounts Payable and Other Accrued Liabilities, Current
VANDA PHARMACEUTICALS INC. (VNDA) had Accounts Payable and Other Accrued Liabilities, Current of $8.68 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $8.68M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $4.47M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $4.94M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $3.14M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $8.68M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.47M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.94M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.14M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $2.18M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $5.99M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.50M 10-K · filed 2026-02-12 |
| 2024-09-30 | $5.81M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.27M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $4.34M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $7.14M 10-K · filed 2025-02-14 |
| 2023-09-30 | $3.49M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.17M 10-Q · filed 2023-07-28 |
| 2023-03-31 | $3.80M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $12.69M 10-K · filed 2024-02-08 |
| 2022-09-30 | $13.43M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $16.41M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $14.33M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $925.00K 10-K · filed 2023-02-09 |
| 2021-09-30 | $1.30M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.12M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $1.80M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.05M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |